secwatch.observer — SEC 8-K summary
======================================

Issuer:     TREACE MEDICAL CONCEPTS, INC. (TMCI)
CIK:        0001630627
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0000950170-24-002719
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Treace Medical reports preliminary Q4 2023 revenue ~$62M, full-year ~$187M above guidance
--------------------------------------------------------------------------------

- Preliminary Q4 revenue $61.8M–$62.2M, ~25% YoY increase; full-year revenue $186.7M–$187.1M, ~32% increase and above guidance of $182M–$186M.
- Blended avg. revenue per Lapiplasty kit in Q4 was $6,437, a record high and 9% increase over Q4 2022.
- Added ~164 new active surgeons in Q4 and ~468 for full year; total active surgeons ~2,855, up 20% YoY.
- Direct sales reps at 227, up 35% over end of 2022; direct channel contributed 82% of Q4 revenue.
- 2024 financial guidance to be provided on the Feb 27, 2024 earnings call.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024002719/0000950170-24-002719-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1630627/000095017024002719/tmci-20240108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-002719

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer